Abstract:Immunohistochemistry has long been held as the gold standard for understanding the expression patterns of therapeutically relevant proteins to identify prognostic and predictive biomarkers. Patient selection for targeted therapy in oncology has successfully relied upon standard microscopy-based methodologies, such as single-marker brightfield chromogenic immunohistochemistry. As promising as these results are, the analysis of one protein, with few exceptions, no longer provides enough information to draw effective conclusions about the probability of treatment response. More multifaceted scientific queries have driven the development of high-throughput and high-order technologies to interrogate biomarker expression patterns and spatial interactions between cell phenotypes in the tumor microenvironment. Such multi-parameter data analysis has been historically reserved for technologies that lack the spatial context that is provided by immunohistochemistry. Over the past decade, technical developments in multiplex fluorescence immunohistochemistry and discoveries made with improving image data analysis platforms have highlighted the importance of spatial relationships between certain biomarkers in understanding a patient's likelihood to respond to, typically, immune checkpoint inhibitors. At the same time, personalized medicine has instigated changes in both clinical trial design and its conduct in a push to make drug development and cancer treatment more efficient, precise, and economical. Precision medicine in immuno-oncology is being steered by data-driven approaches to gain insight into the tumor and its dynamic interaction with the immune system. This is particularly necessary given the rapid growth in the number of trials involving more than one immune checkpoint drug, and/or using those in combination with conventional cancer treatments. As multiplex methods, like immunofluorescence, push the boundaries of immunohistochemistry, it becomes critical to understand the foundation of this technology and how it can be deployed for use as a regulated test to identify the prospect of response from mono- and combination therapies. To that end, this work will focus on: 1) the scientific, clinical, and economic requirements for developing clinical multiplex immunofluorescence assays; 2) the attributes of the Akoya Phenoptics workflow to support predictive tests, including design principles, verification, and validation needs; 3) regulatory, safety and quality considerations; 4) application of multiplex immunohistochemistry through lab-developed-tests and regulated in vitro diagnostic devices.

Recent developments in multiplexing techniques for immunohistochemistry

Multiplex Immunohistochemistry and Immunofluorescence: A Practical Update for Pathologists

Overview of multiplex immunohistochemistry/immunofluorescence techniques in the era of cancer immunotherapy

Clinical and research applications of multiplexed immunohistochemistry and in situ hybridization

Multiplex Cyclic Fluorescent Immunohistochemistry

State-of-the-Art of Profiling Immune Contexture in the Era of Multiplexed Staining and Digital Analysis to Study Paraffin Tumor Tissues

Seven-colour multiplex immunochemistry/immunofluorescence and whole slide imaging of frozen sections

A multiplex immunoprofiling approach for detecting the co-localization of breast cancer biomarkers using a combination of Alexafluor - Quantum dot conjugates and a panel of chromogenic dyes

[Overview of Multiplex Immunohistochemistry and Immunofluorescence Techniques in the Lung Cancer Immunotherapy].

Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment

Rapid multiplex immunohistochemistry for characterizing tumor-immune microenvironment

Brightfield multiplex immunohistochemistry with multispectral imaging

Multiplex Immunohistochemistry for Mapping the Tumor Microenvironment

Making Multiplexed Imaging Flexible: Combining Essential Markers With Established Antibody Panels

Highly Multiplexed Immunohistochemical MALDI-MS Imaging of Biomarkers in Tissues

Companion diagnostic requirements for spatial biology using multiplex immunofluorescence and multispectral imaging

ICPMS based multiplexed bioassay: Principles, approaches and progresses

Multi-Tissue Controls and Multiplex Immunocytochemistry in Pulmonary Cytology

Fluorescent Multiplex Immunohistochemistry Coupled With Other State-Of-The-Art Techniques to Systematically Characterize the Tumor Immune Microenvironment

Multiplex in Situ Tagging Technology for Highly Multiplexed Single-Cell Analysis

Multiplex Immunohistochemical Analysis of the Spatial Immune Cell Landscape of the Tumor Microenvironment